FDMT
4D Molecular Therapeutics, Inc. NASDAQ Listed Dec 11, 2020$14.71
After hrs
$14.65
-0.41%
Mkt Cap $852.2M
52w Low $7.19
78.6% of range
52w High $16.76
50d MA $13.01
200d MA $10.34
P/E (TTM)
-5.4x
EV/EBITDA
—
P/B
1.7x
Debt/Equity
0.0x
ROE
-27.7%
P/FCF
-7.8x
RSI (14)
50.10
ATR (14)
$0.91
Beta
2.93
50d MA
$13.01
200d MA
$10.34
Avg Volume
1.1M
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
5858 Horton Street · EmeryVille, CA 94608 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | AMC | -1.02 | -1.04 | -2.0% | 11.65 | -0.2% | +4.6% | +19.4% | +1.2% | +13.9% | -3.9% | — |
| May 7, 2026 | AMC | -0.97 | -1.01 | -4.1% | 9.93 | -8.6% | +2.1% | +6.4% | -4.2% | +1.1% | -6.1% | — |
| Mar 18, 2026 | AMC | -0.53 | 0.43 | +181.1% | 8.56 | +16.1% | +4.9% | -4.1% | +7.2% | -0.5% | +7.6% | — |
| Nov 10, 2025 | AMC | -1.02 | -1.01 | +1.0% | 10.17 | +1.5% | +6.2% | +1.6% | -6.3% | +5.0% | +1.5% | — |
| Aug 11, 2025 | AMC | -0.88 | -0.98 | -11.4% | 5.53 | +0.0% | +11.2% | +8.5% | +6.4% | +2.3% | +0.1% | — |
| May 8, 2025 | AMC | -0.84 | -0.86 | -2.4% | 3.24 | +0.3% | -4.9% | +7.8% | -1.5% | -4.3% | +2.2% | — |
| Feb 28, 2025 | AMC | -0.80 | -0.90 | -12.5% | 4.53 | +0.9% | -8.6% | -4.1% | +4.8% | -0.5% | -1.7% | — |
| Nov 13, 2024 | AMC | -0.67 | -0.79 | -17.9% | 7.71 | +2.1% | +4.0% | +10.1% | -5.8% | +4.2% | -3.0% | — |
| Aug 8, 2024 | AMC | -0.72 | -0.63 | +12.5% | 14.73 | +6.4% | +0.5% | +1.4% | -0.4% | -3.4% | +1.7% | — |
| May 9, 2024 | AMC | -0.73 | -0.66 | +9.6% | 25.64 | -1.8% | +0.2% | -0.5% | +0.7% | -0.7% | +0.2% | — |
| Feb 29, 2024 | AMC | -0.68 | -0.77 | -13.2% | 28.02 | +2.7% | +4.8% | -2.1% | -5.9% | +4.5% | +4.4% | — |
| Nov 9, 2023 | AMC | -0.67 | -0.24 | +64.2% | 10.50 | +5.7% | +5.2% | -4.7% | +5.3% | -0.3% | -0.3% | — |
| Aug 9, 2023 | AMC | -0.77 | -0.77 | +0.0% | 17.04 | -2.2% | -2.3% | +0.5% | +0.1% | -0.5% | -4.3% | — |
| May 10, 2023 | AMC | -0.88 | -0.88 | +0.0% | 17.65 | +0.8% | -4.2% | +6.0% | -0.5% | +0.4% | +1.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 14 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | $20 | $13.17 | $13.64 | +3.6% | +4.5% | -0.9% | +1.0% | +6.7% | +3.7% |
| Jul 31 | B. Riley Securities | Initiates | Buy | $37 | $10.07 | $10.54 | +4.7% | +1.1% | -0.9% | +1.7% | +0.2% | +2.6% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.98 | $8.63 | -3.9% | -4.1% | +7.2% | -0.5% | +7.6% | +3.0% |
| Mar 19 | Chardan Capital | Maintains | Buy → Buy | — | $8.56 | $9.94 | +16.1% | +4.9% | -4.1% | +7.2% | -0.5% | +7.6% |
| Mar 19 | RBC Capital | Maintains | Outperform → Outperform | — | $8.56 | $9.94 | +16.1% | +4.9% | -4.1% | +7.2% | -0.5% | +7.6% |
| Dec 18 | Chardan Capital | Maintains | Buy → Buy | — | $9.21 | $9.51 | +3.3% | -5.6% | -0.1% | +0.3% | -9.3% | +2.5% |
| Nov 11 | RBC Capital | Maintains | Outperform → Outperform | — | $10.17 | $10.32 | +1.5% | +6.2% | +1.6% | -6.3% | +5.0% | +1.5% |
| Nov 11 | Chardan Capital | Maintains | Buy → Buy | — | $10.17 | $10.32 | +1.5% | +6.2% | +1.6% | -6.3% | +5.0% | +1.5% |
| Nov 11 | Barclays | Maintains | Overweight → Overweight | — | $10.17 | $10.32 | +1.5% | +6.2% | +1.6% | -6.3% | +5.0% | +1.5% |
| Oct 21 | RBC Capital | Maintains | Outperform → Outperform | — | $11.27 | $11.14 | -1.2% | -0.3% | -6.4% | -4.9% | +13.4% | +8.2% |
| Aug 12 | Roth Capital | Maintains | Buy → Buy | — | $5.53 | $5.53 | +0.0% | +11.2% | +8.5% | +6.4% | +2.3% | +0.1% |
| Aug 12 | Chardan Capital | Maintains | Buy → Buy | — | $5.53 | $5.53 | +0.0% | +11.2% | +8.5% | +6.4% | +2.3% | +0.1% |
| Aug 1 | Chardan Capital | Maintains | Buy → Buy | — | $4.50 | $5.28 | +17.3% | +42.7% | -18.4% | +15.5% | -5.3% | +0.9% |
| Jul 3 | Chardan Capital | Maintains | Buy → Buy | — | $4.31 | $4.31 | +0.0% | -1.6% | -6.8% | +6.8% | +4.7% | -1.6% |
| May 9 | Barclays | Maintains | Overweight → Overweight | — | $3.24 | $3.25 | +0.3% | -4.9% | +7.8% | -1.5% | -4.3% | +2.2% |
| May 9 | Goldman Sachs | Maintains | Buy → Buy | — | $3.24 | $3.25 | +0.3% | -4.9% | +7.8% | -1.5% | -4.3% | +2.2% |
| May 9 | Chardan Capital | Maintains | Buy → Buy | — | $3.24 | $3.25 | +0.3% | -4.9% | +7.8% | -1.5% | -4.3% | +2.2% |
| Mar 10 | BofA Securities | Maintains | Buy → Buy | — | $4.07 | $4.10 | +0.7% | -4.2% | +5.4% | +3.2% | +0.9% | -4.0% |
| Mar 4 | Chardan Capital | Maintains | Buy → Buy | — | $4.14 | $4.11 | -0.7% | -4.1% | +4.8% | -0.5% | -1.7% | -4.2% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.53 | $4.57 | +0.9% | -8.6% | -4.1% | +4.8% | -0.5% | -1.7% |
| Mar 3 | RBC Capital | Maintains | Outperform → Outperform | — | $4.53 | $4.57 | +0.9% | -8.6% | -4.1% | +4.8% | -0.5% | -1.7% |
| Feb 11 | Chardan Capital | Maintains | Buy → Buy | — | $5.32 | $5.19 | -2.4% | -13.9% | -0.7% | +3.7% | +3.4% | -0.6% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.97 | $6.09 | +2.0% | -10.9% | -13.9% | -0.7% | +3.7% | +3.4% |
| Jan 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $5.52 | $5.30 | -4.0% | -13.8% | +2.5% | +3.3% | -7.1% | -2.1% |
| Jan 13 | Morgan Stanley | Maintains | Underweight → Underweight | — | $5.52 | $5.30 | -4.0% | -13.8% | +2.5% | +3.3% | -7.1% | -2.1% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.52 | $5.30 | -4.0% | -13.8% | +2.5% | +3.3% | -7.1% | -2.1% |
| Dec 18 | BofA Securities | Maintains | Buy → Buy | — | $6.32 | $6.34 | +0.3% | -5.5% | -3.2% | +9.2% | -6.8% | -1.2% |
| Nov 14 | Chardan Capital | Maintains | Buy → Buy | — | $7.71 | $7.87 | +2.1% | +4.0% | +10.1% | -5.8% | +4.2% | -3.0% |
| Nov 14 | RBC Capital | Maintains | Outperform → Outperform | — | $7.71 | $7.87 | +2.1% | +4.0% | +10.1% | -5.8% | +4.2% | -3.0% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.71 | $7.87 | +2.1% | +4.0% | +10.1% | -5.8% | +4.2% | -3.0% |
| Sep 23 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $11.90 | $11.46 | -3.7% | -2.4% | -1.0% | -1.8% | -2.8% | -1.2% |
| Sep 19 | Leerink Partners | Maintains | Outperform → Outperform | — | $16.82 | $17.39 | +3.4% | -19.7% | -11.9% | -2.4% | -1.0% | -1.8% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.82 | $17.39 | +3.4% | -19.7% | -11.9% | -2.4% | -1.0% | -1.8% |
| Sep 19 | Chardan Capital | Maintains | Buy → Buy | — | $16.82 | $17.39 | +3.4% | -19.7% | -11.9% | -2.4% | -1.0% | -1.8% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.73 | $15.68 | +6.4% | +0.5% | +1.4% | -0.4% | -3.4% | +1.7% |
| Jul 22 | RBC Capital | Maintains | Outperform → Outperform | — | $14.40 | $14.60 | +1.4% | +18.6% | +5.0% | +0.0% | +3.2% | -0.9% |
| Jul 18 | BMO Capital | Maintains | Outperform → Outperform | — | $18.20 | $18.20 | +0.0% | -16.8% | -4.9% | +18.6% | +5.0% | +0.0% |
| Jul 17 | Chardan Capital | Maintains | Buy → Buy | — | $26.75 | $28.89 | +8.0% | -32.0% | -16.8% | -4.9% | +18.6% | +5.0% |
| Jun 26 | RBC Capital | Maintains | Outperform → Outperform | — | $22.00 | $21.93 | -0.3% | -4.5% | -0.4% | +0.3% | +1.7% | -3.6% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.57 | $22.25 | -1.4% | +0.7% | -0.7% | +3.2% | +3.3% | +1.4% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.70 | $25.94 | +0.9% | -0.5% | +0.7% | -0.7% | +0.2% | -1.2% |
| Apr 15 | RBC Capital | Maintains | Outperform → Outperform | — | $26.35 | $27.89 | +5.8% | -0.4% | +1.9% | -5.4% | -2.1% | +1.9% |
| Apr 1 | BMO Capital | Maintains | Outperform → Outperform | — | $31.86 | $31.78 | -0.3% | -5.8% | -6.8% | -0.2% | -1.0% | +3.5% |
| Apr 1 | Jefferies | Maintains | Buy → Buy | — | $31.86 | $31.78 | -0.3% | -5.8% | -6.8% | -0.2% | -1.0% | +3.5% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.02 | $28.77 | +2.7% | +4.8% | -2.1% | -5.9% | +4.5% | +4.4% |
| Feb 5 | BMO Capital | Maintains | Outperform → Outperform | — | $17.49 | $30.05 | +71.8% | +84.6% | +2.8% | -15.0% | -4.7% | +6.4% |
| Feb 5 | RBC Capital | Maintains | Outperform → Outperform | — | $17.49 | $30.05 | +71.8% | +84.6% | +2.8% | -15.0% | -4.7% | +6.4% |
| Jan 29 | RBC Capital | Maintains | Outperform → Outperform | — | $17.50 | $17.93 | +2.5% | +3.0% | -0.9% | -3.4% | +8.2% | -6.3% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $16.65 | $16.64 | -0.1% | +0.5% | +0.1% | -0.5% | -4.3% | -0.9% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.04 | $16.66 | -2.2% | -2.3% | +0.5% | +0.1% | -0.5% | -4.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Bizily Scott | Chief Legal Officer | Sell | 1,635 | $13.65 | $22K | 8,617 | -5.54% | — |
| Sep 14, 2026 | Kirn David | See Remarks | Sell | 58,333 | $13.90 | $811K | 767,486 | +6.69% | -5.54% |
| Sep 1, 2026 | Bizily Scott | Chief Legal Officer | Sell | 584 | $14.00 | $8K | 8,617 | +1.84% | -2.37% |
| Aug 19, 2026 | Kirn David | See Remarks | Sell | 25,927 | $16.42 | $426K | 825,819 | -2.78% | -1.61% |
| Aug 19, 2026 | Kirn David | See Remarks | Sell | 43,149 | $15.36 | $663K | 851,746 | -2.78% | -1.61% |
| Aug 17, 2026 | Bizily Scott | Chief Legal Officer | Sell | 1,635 | $12.20 | $20K | 8,617 | +1.17% | -2.78% |
| Aug 13, 2026 | Bizily Scott | Chief Legal Officer | Sell | 1,635 | $12.00 | $20K | 8,617 | +1.17% | -2.78% |
| Aug 4, 2026 | Kirn David | See Remarks | Sell | 26,842 | $10.23 | $275K | 844,895 | +2.63% | +3.49% |
| Aug 3, 2026 | Kirn David | See Remarks | Sell | 12,415 | $10.05 | $125K | 871,737 | +0.19% | +2.96% |
| Jul 10, 2026 | Kirn David | See Remarks | Sell | 442 | $12.84 | $6K | 884,152 | -0.17% | +2.57% |
| Jul 10, 2026 | Kirn David | See Remarks | Sell | 15,283 | $12.01 | $184K | 884,594 | -0.17% | +2.57% |
| Jul 9, 2026 | Kirn David | See Remarks | Sell | 42,608 | $12.87 | $548K | 899,877 | -0.17% | +2.57% |
| Jun 30, 2026 | Bizily Scott | Chief Legal Officer | Sell | 6,566 | $14.00 | $92K | 8,617 | -2.15% | -4.50% |
| Jun 23, 2026 | Bizily Scott | Chief Legal Officer | Sell | 9,810 | $12.00 | $118K | 8,617 | +0.69% | +2.44% |
| Jun 22, 2026 | Kirn David | See Remarks | Sell | 114,746 | $10.47 | $1.2M | 942,485 | +0.17% | +3.26% |
| Jun 1, 2026 | Kirn David | See Remarks | Sell | 1,922 | $10.02 | $19K | 1,057,231 | +2.80% | +6.83% |
8-K
4D Molecular Therapeutics, Inc. -- 8-K Filing
4D Molecular Therapeutics reported 87% reduction in treatment burden for its therapy, requiring only 1.6 mean supplemental injections per patient, potentially strengthening its competitive position in the market.
Jul 20
8-K · 1.01
!! High
4D Molecular Therapeutics, Inc. -- 8-K 1.01: Material Agreement
4D Molecular Therapeutics secured $200 million in financing from Hercules Capital through a loan and security agreement, providing substantial capital for clinical development and operations.
Jun 29
8-K · 2.02
!! High
4D Molecular Therapeutics, Inc. -- 8-K 2.02: Earnings Results
4D Molecular Therapeutics reported first-quarter 2026 financial results, providing investors with updated operational performance and financial condition metrics for the three-month period ending March 31, 2026.
May 7
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
I cannot provide a meaningful analysis because the filing summary lacks critical details about which executive changed roles, their compensation, responsibilities, or whether the change signals strategic shifts or instability.
Mar 30
8-K
Unknown — 8-K Filing
4D Pharma's clinical progress on 4D-150 for wet AMD with pivotal data expected H1 2027 validates its pipeline potential, but investors should monitor cash runway closely given expanded leadership costs and late-stage development expenses.
Mar 18
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 4,546,059 | $60M | New | Jun 2026 |
| 2 | Janus Henderson Group Plc | 5,247,151 | $49M | New | Mar 2026 |
| 3 | Trails Edge Capital Partners, Lp | 2,227,917 | $30M | Added | Jun 2026 |
| 4 | Vanguard Capital Management Llc | 2,099,055 | $28M | New | Jun 2026 |
| 5 | Citadel Advisors Llc | 1,375,194 | $18M | Added | Jun 2026 |
| 6 | Morgan Stanley | 1,345,390 | $10M | Reduced | Dec 2025 |
| 7 | Bank Of America Corp /de/ | 974,173 | $9M | Added | Mar 2026 |
| 8 | Renaissance Technologies Llc | 614,573 | $8M | Added | Jun 2026 |
| 9 | Vanguard Portfolio Management Llc | 579,903 | $8M | New | Jun 2026 |
| 10 | Nuveen, Llc | 503,071 | $7M | Reduced | Jun 2026 |
| 11 | Rtw Investments, Lp | 475,737 | $4M | — | Mar 2026 |
| 12 | Propel Bio Management, Llc | 380,420 | $4M | New | Mar 2026 |
| 13 | Jpmorgan Chase & Co | 415,655 | $4M | Added | Mar 2026 |
| 14 | Northern Trust Corp | 342,034 | $3M | Added | Mar 2026 |
| 15 | Invesco Ltd. | 310,684 | $3M | Added | Mar 2026 |
| 16 | Vanguard Fiduciary Trust Co | 269,295 | $3M | New | Mar 2026 |
| 17 | Raymond James Financial Inc | 266,147 | $2M | Reduced | Mar 2026 |
| 18 | Perigon Wealth Management, Llc | 146,185 | $2M | — | Jun 2026 |
| 19 | Persistent Asset Partners Ltd | 145,585 | $2M | New | Jun 2026 |
| 20 | Woodline Partners Lp | 200,001 | $2M | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$852.2M
Enterprise Value
$465.3M
P/E (TTM)
-5.41x
Forward P/E
—
PEG Ratio
0.17x
P/B
1.69x
P/S
9.26x
P/FCF
-7.81x
EV/EBITDA
—
Shares Out
57.9M
Financials (TTM)
Revenue
$92.0M
Net Income
-$179.2M
EBITDA
-$184.9M
Free Cash Flow
-$109.1M
Op Cash Flow
-$109.1M
EPS Basic
$-2.42
EPS Diluted
$-2.72
EPS Forward
$-3.83
Gross Margin
42.0%
Op Margin
-214.2%
Net Margin
-194.7%
Balance Sheet
Total Assets
$566.7M
Total Liab.
$61.0M
Total Equity
$505.7M
Cash
$402.7M
LT Debt
$15.8M
Book Value/Sh
$8.73
Debt/Equity
0.04x
Current Ratio
9.39
Quick Ratio
9.39
Returns & Growth
ROE
-27.7%
ROA
-24.7%
ROIC
-30.2%
Rev Growth YoY
+230194.6%
EPS Growth YoY
+18.8%
Price Returns
2W
+5.8%
1M
-2.5%
3M
+29.1%
6M
+63.4%
12M
+77.7%
Technicals
52W High
$16.76
52W Low
$7.19
50d MA
$13.01
200d MA
$10.34
RSI (14)
50.10
ATR (14)
$0.91
Beta
2.93
Avg Volume
1.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$25.00
High
$33.00
Low
$17.00
Median
$25.00
Data updated apr 25, 2026 8:44am
· Source: financialmodelingprep.com